CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor

Author： Furuta Takahisa   Sugimoto Mitsushige   Shirai Naohito   Ishizaki Takashi  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.8, Iss.9, 2007-09, pp. : 1199-1210

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/- Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treatments

By  

Current Drug Metabolism, Vol. 13, Iss. 9, 2012-11 ,pp. : 1303-1312

Bentham Science Publishers

Access to resources Recommend Favorite

Gastro-Oesophageal Reflux Disease: Beyond Proton Pump Inhibitor Therapy

By Hershcovici Tiberiu  

Drugs, Vol. 71, Iss. 18, 2011-12 ,pp. : 2381-2389

Adis International

Access to resources Recommend Favorite

Polymorphism of CYP2C19 and Gastric Emptying in Patients with Proton Pump Inhibitor-resistant Gastric Ulcers

By Wada F   Murase K   Isomoto H   Soda H   Takeshima F   Omagari K   Mizuta Y   Tsukamoto K   Murata I   Kohno S  

The Journal of International Medical Research, Vol. 30, Iss. 4, 2002-07 ,pp. : 413-421

Field House Publishing

Access to resources Recommend Favorite

Proton-Pump Inhibitor Therapy in Patients with Gastro-Oesophageal Reflux Disease: Putative Mechanisms of Failure

By Fass Ronnie  

Drugs, Vol. 67, Iss. 11, 2007-01 ,pp. : 1521-1530

Adis International

Access to resources Recommend Favorite

Patient Satisfaction with Switching to Esomeprazole from Existing Proton Pump Inhibitor Therapy for Gastro-Oesophageal Reflux Disease: An Observational, Multicentre Study

By Hoogendoorn Robert J.  

Clinical Drug Investigation, Vol. 29, Iss. 12, 2009-12 ,pp. : 803-810

Adis International

Access to resources Recommend Favorite